SimBioSys

SimBioSys is a precision medicine company leveraging the power of AI, data science, and spatial biophysics to transform patient care and combat cancer. The company specializes in creating detailed 3D models of tumors through its TumorSight Viz & Plan, TumorSight IQ, and PhenoScope solutions, designed to deliver precise answers to critical clinical questions and personalize patient treatment. These technologies address the diverse responses to treatment caused by tumor heterogeneity by examining the tumor, moving beyond traditional biopsies or 2D pathology slides.

In January 2024 , the company received FDA clearance for its digital precision medicine platform, TumorSight. This approval is expected to enhance the company's credibility and expand its market reach, thereby benefiting a broader spectrum of patients and healthcare providers by offering insights into precision medicine in cancer care​.

Key customers and partnerships

SimBioSys entered partnerships with over 40 organizations, including Mayo Clinic , Cleveland Clinic, Cedars Sinai, and the University of Chicago Medicine. These partnerships were part of SimBioSys' broader efforts to validate and enhance the efficacy of its solutions in addressing cancer treatment's complexities.

Funding and financials

On October 26, 2021, SimBioSys raised USD 15 million in a Series A funding round co-led by Genoa Ventures and Northpond Ventures. SimBioSys intended to use these funds to expand its technology into other solid tumors beyond breast cancer and to drive commercialization efforts to bring the technology to patients and the biopharma industry.